Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29659230 | 1.00 | MAPT (0.40) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL1814471 | 0.89 | JAK2 (0.37) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL30454411 | 0.89 | JAK2 (0.37) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL13212813 | 0.81 | ALDH1A1 (0.40) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL23860863 | 0.78 | ALDH1A1 (0.40) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL2492111 | 0.78 | GAA (0.47) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL4716840 | 0.78 | MAPT (0.40) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL29364018 | 0.78 | ALDH1A1 (0.40) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL6107503 | 0.78 | ALDH1A1 (0.40) | MAPTALDH1A1GAAHSD17B10GRM5 | |
| SCHEMBL4716839 | 0.78 | ALDH1A1 (0.40) | MAPTALDH1A1GAAHSD17B10GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| WO-2024130166-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024083086-A1 | BICYCLIC DERIVATIVE INTEGRIN INHIBITOR | 上海如凌生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-114302886-B | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-7700592-B2 | α2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2008100463-A1 | 3,4-DIHYDR0-L,4-BENZ0XAZINE, 3, 4-DIHYDR0-1, 4-BENZOTHIAZINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007024949-A2 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | MAPT 3164/4885ALDH1A1 2072/4885GAA 3242/4885 |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | MAPT 2378/4885ALDH1A1 1037/4885GAA 2204/4885 |
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | MAPT 3823/4885ALDH1A1 908/4885GAA 1790/4885 |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | MAPT 1289/4885ALDH1A1 915/4885GAA 3709/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | MAPT 4245/4885ALDH1A1 632/4885GAA 4369/4885 |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | MAPT 1289/4885ALDH1A1 915/4885GAA 3709/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | MAPT 4249/4885ALDH1A1 232/4885GAA 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.